Skip to main content
. 2017 Jun 28;8(38):63290–63298. doi: 10.18632/oncotarget.18796

Figure 4. Downregulation of HMGB1 inhibited MDSCs proliferation in the Renca tumor-bearing mice.

Figure 4

The Renca-bearing mice of each group (n=5) were intraperitoneally injected with 5 and 20 μg αHMGB1Ab, 100 μL of PBS and 20 μg isotype control Ab, respectively. Splenocytes and tumors were isolated from tumor-bearing mice. (A) The surface expression of CD3, B220, CD11c, CD11b, and Gr-1 on splenocytes was detected by flow cytometry. (B) The splenic MDSCs ratio was measured by FACS. (C) The MDSCs, TAM and Treg ratio at tumor site was measured by FACS. (D) The Renca-bearing mice of each group were intraperitoneally injected with 100 μL of PBS, 20 μg isotype control Ab, 20 μg αHMGB1Ab, 10 μg αGr-1, and 10 μg αGr-1Ab plus 20 μg HMGB1 every 3 days from day 0. Tumor development and mortality was monitored regularly and statistically analyzed using a log-rank test (n=5). Data are mean±SEM. Representative results of one of three independent experiments. *P<0.05, **P<0.01.